Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) ATIR(TM) for Reduction of Transplant Related Mortality Following an Allogeneic Stem Cell Transplantation Using a Mismatched Donor
The study is currently open for enrollment in centers in
"We are very pleased to initiate the registration study following
excellent clinical results from the phase I/II study with ATIR(TM)." says Dr.
"As the pioneer of ATIR(TM) I am very excited about this next major
development milestone, a multinational registration study" says Dr.
ATIR(TM), a donor lymphocyte preparation depleted of alloreactive T-cells, is under development to reduce transplant related mortality (TRM) following an allogeneic hematopoietic stem cell transplantation (HSCT). ATIR(TM) is designed to provide early immune reconstitution to fight infections and remaining tumor cells (by eliminating the use of prophylactic immune suppressants) while preventing acute severe (Grade III/IV) Graft versus Host Disease. ATIR(TM) thereby significantly improves the outcome of the transplant procedure. Moreover, it enables the use of a mismatched, related (haplo-identical) donor, thus providing virtually everyone with an immediately available donor and treatment, thereby addressing a high unmet medical need as patients eligible for an allogeneic transplantation but without a matched donor available in general have no treatment options left.
ATIR(TM) has been granted orphan drug designations from both the FDA and the EMEA.
About Kiadis Pharma
Kiadis Pharma is an oncology focused biopharmaceutical development
company with cell based products in clinical development. The company
develops products that offer novel treatment options for terminally ill
cancer patients and address significant unmet medical needs. The key focus
indication for Kiadis Pharma is limitations and complications of bone marrow
transplantation procedures. Kiadis Pharma is located in
English release is provided by Kiadis Pharma. Equivalent translations are from a third party.
SOURCE Kiadis Pharma